Monoclonal Antibodies and Immunoconjugates as Anti-Cancer Agents

Antibodies ◽  
1987 ◽  
pp. 189-200
Author(s):  
Robert K. Oldham
Keyword(s):  
Monoclonal Antibodies ◽  
Anti Cancer

Antibody Therapeutics for Ovarian Carcinoma and Translation to the Clinic

2018 ◽  
Author(s):  
Debra H. Josephs ◽  
Heather J. Bax ◽  
Giulia Pellizzari ◽  
James F. Spicer ◽  
Ana Montes ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibodies ◽  
Tumor Antigens ◽  
Ovarian Carcinomas ◽  
Immune Effector ◽  
Effector Cells ◽  
Tumor Microenvironments ◽  
Specific Tumor ◽  
Anti Cancer ◽  
Reduced Toxicity

Despite improvements over the past decade in the treatment of ovarian cancer, many patients are at risk of recurrent disease and emerging drug resistance. The increased selectivity and reduced toxicity of molecularly targeted anti-cancer agents renders them attractive for development in ovarian cancer, and monoclonal antibodies targeting ovarian cancer-specific tumor antigens represent the largest such group investigated in this clinical setting. This chapter describes examples of monoclonal antibodies clinically evaluated for efficacy in ovarian cancer. These agents recognize molecular targets expressed on tumors or within tumor microenvironments that may be essential for tumor cell survival and proliferation. Recently, antibodies targeting checkpoint molecules on immune cells have shown efficacy in modulating anti-tumor immunity, and applications in ovarian carcinomas are evaluated. The chapter focuses on therapeutic agents’ attributes on targeting key cancer growth and progression pathways, and propensity to engender effector functions by activating immune effector cells in tumors and the circulation.

scholarly journals Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers

Oncotarget ◽  
2020 ◽  
Vol 11 (1) ◽  
pp. 31-45 ◽  
Author(s):  
Kouki Okita ◽  
Shogo Okazaki ◽  
Shinya Uejima ◽  
Erina Yamada ◽  
Hiroki Kaminaka ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Epithelial Cancers ◽  
Anti Cancer

scholarly journals Antibody–drug conjugates as novel anti-cancer chemotherapeutics

2015 ◽  
Vol 35 (4) ◽  
Author(s):  
Christina Peters ◽  
Stuart Brown
Keyword(s):  
Monoclonal Antibodies ◽  
Small Molecule ◽  
Current Knowledge ◽  
Cytotoxic Agent ◽  
Cancer Drugs ◽  
Antibody Drug Conjugates ◽  
Cancer Chemotherapeutics ◽  
Drug Conjugates ◽  
Anti Cancer ◽  
Antibody Drug

Antibody drug conjugates (ADCs) are an efficacious class of anti-cancer drugs that comprise monoclonal antibodies (mAbs) conjugated to small-molecule cytotoxic agent via a stable linker. This review summarizes the current knowledge and developments in the field of ADCs.

The transgenic chicken derived anti-CD20 monoclonal antibodies exhibits greater anti-cancer therapeutic potential with enhanced Fc effector functions

Biomaterials ◽  
2018 ◽  
Vol 167 ◽  
pp. 58-68 ◽  
Author(s):  
Young Min Kim ◽  
Jin Se Park ◽  
Sang Kyung Kim ◽  
Kyung Min Jung ◽  
Young Sun Hwang ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Therapeutic Potential ◽  
Transgenic Chicken ◽  
Effector Functions ◽  
Anti Cancer ◽  
Anti Cd20

scholarly journals Targeting the IGF-Axis for Cancer Therapy: Development and Validation of an IGF-Trap as a Potential Drug

Cells ◽  
2020 ◽  
Vol 9 (5) ◽  
pp. 1098 ◽  
Author(s):  
Yinhsuan Michely Chen ◽  
Shu Qi ◽  
Stephanie Perrino ◽  
Masakazu Hashimoto ◽  
Pnina Brodt
Keyword(s):  
Monoclonal Antibodies ◽  
Insulin Receptor ◽  
Cancer Progression ◽  
Drug Efficacy ◽  
Poor Performance ◽  
Receptor Activation ◽  
Anti Cancer ◽  
Igf I

The insulin-like growth factor (IGF)-axis was implicated in cancer progression and identified as a clinically important therapeutic target. Several IGF-I receptor (IGF-IR) targeting drugs including humanized monoclonal antibodies have advanced to phase II/III clinical trials, but to date, have not progressed to clinical use, due, at least in part, to interference with insulin receptor signaling and compensatory signaling by the insulin receptor (IR) isoform A that can bind IGF-II and initiate mitogenic signaling. Here we briefly review the current state of IGF-targeting biologicals, discuss some factors that may be responsible for their poor performance in the clinic and outline the stepwise bioengineering and validation of an IGF-Trap—a novel anti-cancer therapeutic that could bypass these limitations. The IGF-Trap is a heterotetramer, consisting of the entire extracellular domain of the IGF-IR fused to the Fc portion of human IgG1. It binds human IGF-I and IGF-II with a three-log higher affinity than insulin and could inhibit IGF-IR driven cellular functions such as survival, proliferation and invasion in multiple carcinoma cell models in vitro. In vivo, the IGF-Trap has favorable pharmacokinetic properties and could markedly reduce metastatic outgrowth of colon and lung carcinoma cells in the liver, outperforming IGF-IR and ligand-binding monoclonal antibodies. Moreover, IGF-Trap dose-response profiles correlate with their bio-availability profiles, as measured by the IGF kinase receptor-activation (KIRA) assay, providing a novel, surrogate biomarker for drug efficacy. Our studies identify the IGF-Trap as a potent, safe, anti-cancer therapeutic that could overcome some of the obstacles encountered by IGF-targeting biologicals that have already been evaluated in clinical settings.

scholarly journals The Evolution of Cancer Immunotherapy

Vaccines ◽  
2021 ◽  
Vol 9 (6) ◽  
pp. 614
Author(s):  
Meshaal Khan ◽  
Ajay V. Maker ◽  
Shikha Jain
Keyword(s):  
Monoclonal Antibodies ◽  
Cancer Vaccines ◽  
Checkpoint Inhibitors ◽  
Gene Sequencing ◽  
Hematologic Malignancies ◽  
Review Article ◽  
Therapy Options ◽  
Car T Cells ◽  
Anti Cancer ◽  
Car T

Immunotherapy has changed the environment of cancer treatment by providing new and efficacious therapy options for many solid and hematologic malignancies. Although not a new field of oncology, immunotherapy has quickly developed into one of the most flourishing fields in medicine. In this review article, we explore key discoveries which helped to shape our current understanding of the immune system’s role in neoplasms. Many landmark developments include the advancements in checkpoint inhibitors, monoclonal antibodies, CAR-T cells and anti-cancer vaccines. We also explore the drawbacks and efficacy of various categories of immunotherapy. Ongoing investigations within immunotherapy, such as the gut microbiome, combining checkpoint inhibitors and gene sequencing, continue to personalize treatments for cancer patients, providing exciting and endless possibilities for the future.

Sign in / Sign up

Export Citation Format

Share Document